{"_id": "64ffe4f7748b29c10bbbeaf1", "nctId": "NCT01810913", "title": "Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck", "booleanRepresentation": "{\n    \"$and\": [\n        {\n            \"$and\": [\n                {\n                    \"$and\": [\n                        {\"pathologically proven diagnosis of head and neck squamous cell carcinoma (HNSCC)\"},\n                        {\n                            \"$or\": [\n                                {\"involving the oral cavity (excluding lips)\"},\n                                {\"involving the oropharynx (p16 negative)\"},\n                                {\"involving the larynx\"},\n                                {\"involving the hypopharynx\"}\n                            ]\n                        }\n                    ]\n                },\n                {\n                    \"$or\": [\n                        {\"underwent gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration\"},\n                        {\n                            \"$and\": [\n                                {\"biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection\"},\n                                {\"gross total resection done within 63 days prior to registration\"}\n                            ]\n                        }\n                    ]\n                },\n                {\n                    \"$or\": [\n                        {\"extracapsular nodal extension\"},\n                        {\"invasive cancer at the primary tumor resection margin (tumor on ink)\"}\n                    ]\n                }\n            ]\n        },\n        {\n            \"$and\": [\n                {\"pathologic stage III or IV HNSCC\"},\n                {\"no distant metastases\"},\n                {\n                    \"$and\": [\n                        {\"general history and physical examination by a radiation oncologist and/or medical oncologist within 84 days prior to registration\"},\n                        {\"examination by an ear nose throat (ENT) or head & neck surgeon prior to surgery\"}\n                    ]\n                },\n                {\n                    \"$or\": [\n                        {\"neck computed tomography (CT) (with contrast) or CT/positron emission tomography (PET) (with contrast) and/or magnetic resonance imaging (MRI) of the neck (T1 with gadolinium and T2) within 84 days prior to surgery\"},\n                        {\"chest CT scan (with or without contrast) or CT/PET that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration\"}\n                    ]\n                },\n                {\"Zubrod performance status of 0-1 within 14 days prior to registration\"},\n                {\"age >= 18\"},\n                {\"absolute granulocyte count (AGC) >= 1,500 cells/mm^3 (obtained within 14 days prior to registration on study)\"},\n                {\"platelets >= 100,000 cells/mm^3 (obtained within 14 days prior to registration on study)\"},\n                {\"hemoglobin >= 8.0 g/dl (obtained within 14 days prior to registration on study)\"},\n                {\"total bilirubin < 2 x institutional upper limit of normal (ULN) within 14 days prior to registration\"},\n                {\"aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x institutional ULN within 14 days prior to registration\"},\n                {\n                    \"$or\": [\n                        {\"serum creatinine < institutional ULN within 14 days prior to registration\"},\n                        {\"creatinine clearance (CC) >= 50 ml/min within 14 days prior to registration determined by 24-hour collection or estimated by Cockcroft-Gault formula\"}\n                    ]\n                },\n                {\"negative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potential\"},\n                {\n                    \"$and\": [\n                        {\"sodium (Na), potassium (K), chloride (Cl), glucose, calcium (Ca), magnesium (Mg), and albumin assessments within 14 days prior to registration\"},\n                        {\n                            \"$or\": [\n                                {\"initial magnesium < 0.5 mmol/L (1.2 mg/dl)\"},\n                                {\"magnesium supplementation\"}\n                            ]\n                        }\n                    ]\n                },\n                {\"patients with feeding tubes are eligible for the study\"},\n                {\"women of childbearing potential and sexually active men must agree to use medically effective means of birth control\"},\n                {\"patient must provide study specific informed consent prior to study entry\"}\n            ]\n        }\n    ],\n    \"$not\": {\n        \"$or\": [\n            {\"prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years)\"},\n            {\"simultaneous primaries or bilateral tumors (except bilateral tonsil cancers or T1-2, N0, M0 resected differentiated thyroid carcinoma)\"},\n            {\"prior systemic chemotherapy or anti-epidermal growth factor (EGF) therapy for the study cancer\"},\n            {\"prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields\"},\n            {\n                \"$or\": [\n                    {\"unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to registration\"},\n                    {\"transmural myocardial infarction within 6 months prior to registration\"},\n                    {\"acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\"},\n                    {\"chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\"},\n                    {\"idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy or is thought to require oxygen therapy within 1 year prior to registration\"},\n                    {\"hepatic insufficiency resulting in clinical jaundice and/or coagulation defects\"},\n                    {\"acquired immune deficiency syndrome (AIDS) based upon current CDC definition\"},\n                    {\"grade 3-4 electrolyte abnormalities\"},\n                    {\"pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception\"},\n                    {\"prior allergic reaction to cetuximab\"}\n                ]\n            }\n        ]\n    }\n}"}